Anhui Sunhere Pharmaceutical Excipients Co Ltd (300452) - Net Assets
Based on the latest financial reports, Anhui Sunhere Pharmaceutical Excipients Co Ltd (300452) has net assets worth CN¥1.03 Billion CNY (≈ $151.19 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.63 Billion ≈ $237.90 Million USD) and total liabilities (CN¥592.53 Million ≈ $86.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Anhui Sunhere Pharmaceutical Excipients to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.03 Billion |
| % of Total Assets | 63.55% |
| Annual Growth Rate | 19.52% |
| 5-Year Change | 48.86% |
| 10-Year Change | 168.53% |
| Growth Volatility | 25.05 |
Anhui Sunhere Pharmaceutical Excipients Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Anhui Sunhere Pharmaceutical Excipients Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Anhui Sunhere Pharmaceutical Excipients asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Anhui Sunhere Pharmaceutical Excipients Co Ltd (2011–2024)
The table below shows the annual net assets of Anhui Sunhere Pharmaceutical Excipients Co Ltd from 2011 to 2024. For live valuation and market cap data, see Anhui Sunhere Pharmaceutical Excipients (300452) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥975.30 Million ≈ $142.72 Million |
+4.28% |
| 2023-12-31 | CN¥935.25 Million ≈ $136.86 Million |
+18.59% |
| 2022-12-31 | CN¥788.62 Million ≈ $115.40 Million |
+11.72% |
| 2021-12-31 | CN¥705.92 Million ≈ $103.30 Million |
+7.75% |
| 2020-12-31 | CN¥655.17 Million ≈ $95.87 Million |
+9.82% |
| 2019-12-31 | CN¥596.57 Million ≈ $87.30 Million |
+6.93% |
| 2018-12-31 | CN¥557.89 Million ≈ $81.64 Million |
+11.53% |
| 2017-12-31 | CN¥500.23 Million ≈ $73.20 Million |
+24.22% |
| 2016-12-31 | CN¥402.70 Million ≈ $58.93 Million |
+10.88% |
| 2015-12-31 | CN¥363.20 Million ≈ $53.15 Million |
+104.97% |
| 2014-12-31 | CN¥177.20 Million ≈ $25.93 Million |
+18.74% |
| 2013-12-31 | CN¥149.23 Million ≈ $21.84 Million |
+23.16% |
| 2012-12-31 | CN¥121.17 Million ≈ $17.73 Million |
+26.26% |
| 2011-12-31 | CN¥95.96 Million ≈ $14.04 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Anhui Sunhere Pharmaceutical Excipients Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1308.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥488.34 Million | 53.96% |
| Common Stock | CN¥234.45 Million | 25.91% |
| Other Comprehensive Income | CN¥105.39 Million | 11.65% |
| Other Components | CN¥76.83 Million | 8.49% |
| Total Equity | CN¥905.01 Million | 100.00% |
Anhui Sunhere Pharmaceutical Excipients Co Ltd Competitors by Market Cap
The table below lists competitors of Anhui Sunhere Pharmaceutical Excipients Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Akis Gayrimenkul Yatirim Ortakligi AS
IS:AKSGY
|
$484.10 Million |
|
Kofola CeskoSlovensko as
PR:KOFOL
|
$484.11 Million |
|
Nexen Tire
KO:002350
|
$484.20 Million |
|
POET Technologies Inc
V:PTK
|
$484.32 Million |
|
Taiwan Semiconductor Co Ltd
TWO:5425
|
$483.80 Million |
|
Just Dial Limited
NSE:JUSTDIAL
|
$483.73 Million |
|
Shanghai Wondertek Software Co Ltd
SHG:603189
|
$483.58 Million |
|
Bowman Consulting Group Ltd
NASDAQ:BWMN
|
$483.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anhui Sunhere Pharmaceutical Excipients Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 866,094,945 to 905,009,796, a change of 38,914,851 (4.5%).
- Net income of 119,424,741 contributed positively to equity growth.
- Dividend payments of 59,007,525 reduced retained earnings.
- Share repurchases of 22,769,786 reduced equity.
- Other comprehensive income increased equity by 70,002,765.
- Other factors decreased equity by 68,735,344.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥119.42 Million | +13.2% |
| Dividends Paid | CN¥59.01 Million | -6.52% |
| Share Repurchases | CN¥22.77 Million | -2.52% |
| Other Comprehensive Income | CN¥70.00 Million | +7.74% |
| Other Changes | CN¥-68.74 Million | -7.59% |
| Total Change | CN¥- | 4.49% |
Book Value vs Market Value Analysis
This analysis compares Anhui Sunhere Pharmaceutical Excipients Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25.85x to 3.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.55 | CN¥14.11 | x |
| 2012-12-31 | CN¥0.68 | CN¥14.11 | x |
| 2013-12-31 | CN¥0.85 | CN¥14.11 | x |
| 2014-12-31 | CN¥1.00 | CN¥14.11 | x |
| 2015-12-31 | CN¥1.62 | CN¥14.11 | x |
| 2016-12-31 | CN¥1.73 | CN¥14.11 | x |
| 2017-12-31 | CN¥1.87 | CN¥14.11 | x |
| 2018-12-31 | CN¥2.08 | CN¥14.11 | x |
| 2019-12-31 | CN¥2.25 | CN¥14.11 | x |
| 2020-12-31 | CN¥2.54 | CN¥14.11 | x |
| 2021-12-31 | CN¥2.73 | CN¥14.11 | x |
| 2022-12-31 | CN¥3.10 | CN¥14.11 | x |
| 2023-12-31 | CN¥3.59 | CN¥14.11 | x |
| 2024-12-31 | CN¥3.86 | CN¥14.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anhui Sunhere Pharmaceutical Excipients Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.20%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.53%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.72x
- Recent ROE (13.20%) is below the historical average (17.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 22.76% | 15.25% | 1.18x | 1.27x | CN¥12.25 Million |
| 2012 | 26.54% | 17.49% | 0.87x | 1.75x | CN¥20.05 Million |
| 2013 | 23.47% | 16.45% | 0.91x | 1.57x | CN¥20.10 Million |
| 2014 | 19.71% | 14.59% | 0.90x | 1.50x | CN¥17.21 Million |
| 2015 | 12.19% | 17.10% | 0.57x | 1.26x | CN¥7.95 Million |
| 2016 | 12.11% | 17.03% | 0.56x | 1.27x | CN¥8.52 Million |
| 2017 | 11.40% | 14.83% | 0.51x | 1.51x | CN¥6.19 Million |
| 2018 | 14.22% | 16.36% | 0.60x | 1.44x | CN¥20.80 Million |
| 2019 | 16.05% | 18.18% | 0.57x | 1.54x | CN¥31.79 Million |
| 2020 | 16.05% | 17.69% | 0.59x | 1.54x | CN¥35.42 Million |
| 2021 | 13.95% | 14.47% | 0.64x | 1.50x | CN¥25.25 Million |
| 2022 | 18.09% | 18.55% | 0.60x | 1.63x | CN¥58.46 Million |
| 2023 | 18.65% | 19.25% | 0.54x | 1.78x | CN¥74.93 Million |
| 2024 | 13.20% | 13.53% | 0.57x | 1.72x | CN¥28.92 Million |
Industry Comparison
This section compares Anhui Sunhere Pharmaceutical Excipients Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anhui Sunhere Pharmaceutical Excipients Co Ltd (300452) | CN¥1.03 Billion | 22.76% | 0.57x | $484.09 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Anhui Sunhere Pharmaceutical Excipients Co Ltd
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. research and development, production, and sale of new pharmaceutical excipients in China. The company provides cellulose, starch, povidone, stearic acid, coating powder, resin, food additive, and other products. It also exports its products. Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. was founded in 2001 and is based in Huainan, China.